Lipocine Inc.
LPCN
NASDAQ·Healthcare·Biotechnology·Mkt cap $20.2M
$2.45
▲ +1.24%
P/E
-1.31
Mkt Cap
$20.2M
52-Wk Range
$1.81–$12.37
52-Week Range
$1.81 - $12.37
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 15.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oral bioavailability enhancement technology for poorly absorbed drugs
- Diversified clinical pipeline reducing single-product risk
- Focus on underserved therapeutic areas with significant market potential
- Unique formulations enabling improved dosing schedules and patient compliance
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Revenue decline expected
FDA regulatory approvals and commercialization of lead products
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+19.5% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LPCN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 4, 2026
Reported EPS of -$0.32 vs -$0.40 consensus (+20.0% surprise). Revenue of $213.0K vs $213.0K expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.0%
Revenue trend · last 8Q
—
—
-99%
+595%
—
-67%
+27%
-69%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$3.5M
$93.9K
$622.8K
$114.6K
$1.1M
$119.4K
$190.1K
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
-1379.6%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Industrial Alliance · $6.00 · Apr 13, 2026
vs Industry
How LPCN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.